Anti-Microbial Savior BioteQ Co., Ltd.

As of June 30, 2026, Anti-Microbial Savior BioteQ Co., Ltd. carries a market capitalization of 1.66B, placing it among publicly traded companies globally. Its enterprise value stands at 1.31B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Anti-Microbial Savior BioteQ Co., Ltd. has 37.88M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Anti-Microbial Savior BioteQ Co., Ltd. maintains a current ratio of 37.54, meaning it holds 37.5x the short-term assets needed to cover near-term liabilities.

As of the close on October 22, 2026, Anti-Microbial Savior BioteQ Co., Ltd.'s stock has declined approximately 49.46% over the past 52 weeks. The 50-day moving average sits at 47.17, while the 200-day moving average is 55.54.

As of June 30, 2026, Anti-Microbial Savior BioteQ Co., Ltd. holds 401.11M in cash and equivalents against 48.47M in total debt, resulting in a net debt position of -401.11M. Total book value stands at 470.64M, with working capital of 405.81M providing operational flexibility.

Anti-Microbial Savior BioteQ Co., Ltd.'s most recent stock split took place on November 13, 2025 with a 773:784 split ratio.